Omalizumab Treatment for Chronic Urticaria
Author Information
Author(s): Michael C Saavedra, Sanjiv Sur
Primary Institution: The University of Texas Medical Branch
Hypothesis
Can omalizumab effectively treat chronic idiopathic urticaria by down regulating the high-affinity IgE receptor?
Conclusion
Omalizumab treatment is associated with a decrease in FcεRI expression and significant improvement in chronic idiopathic urticaria.
Supporting Evidence
- Prior treatments with antihistamines and immunosuppressive medications were ineffective.
- Omalizumab led to significant clinical improvement and allowed for the reduction of cyclosporine dosage.
- FcεRI expression decreased by approximately 80% after 14 days of treatment.
Takeaway
A woman with severe hives found relief after taking a medicine called omalizumab, which helped reduce a specific receptor in her blood that was causing her symptoms.
Methodology
The study involved flow cytometric analysis of FcεRI levels on blood basophils before and during omalizumab treatment.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
A 51-year-old woman with a history of asthma, allergic rhinitis, and atopic dermatitis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website